Stockscreener 앱 받기
12.48
1.89%
-0.24
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by B. Riley - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
Q3 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Citigroup Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Citi Raises Syndax Target to $51, Adds Positive Catalyst Watch - AInvest
Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance
BTIG Research Raises Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $56.00 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Earnings Beat - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking - simplywall.st
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Citigroup Raises SNDX Price Target Amid "Buy" Rating - AInvest
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Citigroup Raises Syndax PT to $51 from $46, Maintains Buy Rating - AInvest
Syndax Pharmaceuticals (SNDX) Surges on Strong Q2 2025 Results - GuruFocus
BTIG Raises Price Target for SNDX, Maintains Buy Rating | SNDX S - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Exceed Expectations, Citi Issues Upside Catalyst Watch - AInvest
Syndax stock up as Citi issues catalyst watch (SNDX:NASDAQ) - Seeking Alpha
Syndax Stock (SNDX) Moves Higher: Analysts Raise PTs on Strong Revenue, Approaching Catalyst - AskTraders.com
Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals shares surge 17.44% intraday after Q2 earnings beat expectations, driven by strong revenue from Revuforj and Niktimvo. - AInvest
Syndax stock price target raised to $20 from $18 at Goldman Sachs - Investing.com Canada
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt? - simplywall.st
Syndax Pharmaceuticals Shares Soar 12.62% on Strong Q2 Earnings - AInvest
Syndax: Q2 Earnings Snapshot - New Haven Register
Syndax Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Syndax Pharmaceuticals' Q2 2025: Unpacking Key Contradictions in Revuforj's Impact on Patient Care and Market Growth - AInvest
Syndax Pharmaceuticals Wins Over Wall Street With Strong Drug Gains - Finimize
Syndax Reports Losses, But Wall Street Still Sees Big Upside - Finimize
Syndax Pharmaceuticals: Navigating the Path to Profitability with Two Blockbuster Candidates - AInvest
Syndax Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Syndax Pharmaceuticals earnings beat by $0.18, revenue topped estimates - Investing.com UK
Syndax Q2 2025 presentation: Strong revenue growth despite widening losses - Investing.com Canada
SNDX Surpasses Revenue Expectations with Strong Product Sales - GuruFocus
Syndax Pharmaceuticals Inc SEC 10-Q Report - TradingView
Syndax Reports 43% Revuforj Growth, $28.6mln Net Revenue in Q2. - AInvest
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Reports Explosive 43% Revenue Growth as Both Cancer Drugs Exceed Market Expectations - Stock Titan
Syndax Pharmaceuticals Inc. Enters Reversal Setup in Weekly ChartsSwing Trade Entry Alert Analysis - beatles.ru
0.24%
3.39%
자본화:
|
볼륨(24시간):